TPST
TPST
NASDAQ · Biotechnology

Tempest Therapeutics Inc

$1.11
+0.01 (+0.91%)
As of Jun 30, 10:52 PM ET ·
Financial Highlights (FY 2026)
Revenue
26.99M
Net Income
-91,104,568
Gross Margin
-166.7%
Profit Margin
-16,993.3%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -166.7% 55.6% 55.6% 55.6%
Operating Margin -16,870.0% -19.4% -23.6% -23.4%
Profit Margin -16,993.3% -27.6% -27.4% -21.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 26.99M 4.18M 3.97M 4.44M
Gross Profit -44,987,433 2.32M 2.21M 2.47M
Operating Income -4,553,536,904 -808,931 -937,046 -1,041,926
Net Income -91,104,568 -1,151,363 -1,086,006 -951,664
Gross Margin -166.7% 55.6% 55.6% 55.6%
Operating Margin -16,870.0% -19.4% -23.6% -23.4%
Profit Margin -16,993.3% -27.6% -27.4% -21.4%
Rev Growth +11.5% +10.2% +12.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 2.99M 2.87M 2.89M
Total Equity 4.14M 4.36M 4.56M
D/E Ratio 0.72 0.66 0.63
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -91,267,239 -1,394,086 -1,159,340 -1,348,527
Free Cash Flow -921,744 -1,324,564 -1,179,947